Azome Therapeutics Alternatives & Competitors
12 companies similar to Azome Therapeutics — Developing selective NLRP3 inflammasome inhibitors for severe inflammatory disea...
Companies similar to Azome Therapeutics
NodThera
Treating chronic disease by targeting inflammation at its source
Philadelphia, United Stat...
Upstream Bio
Developing treatments for inflammatory diseases
Waltham, United States
Olatec Therapeutics
Leading the Development of Specific NLRP3 Antagonists, Mediator of Innate Inflammatory Re...
New York, United States
-Ltd.-logo. "CV6 Therapeutics, (NI) Ltd."){kind=logo}
CV6 Therapeutics, (NI) Ltd.
CV6 Therapeutics is dedicated to improving patients lives through the development of novel...
United Kingdom
Rival Readout
Competing with Azome Therapeutics? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Pharvaris
Pioneering science for patient choice
Zug, Switzerland
Cleave Therapeutics, Inc.
VCP/p97 Inhibitors for Oncology and Neurodegenerative Diseases
San Francisco, United Sta...
Georgiamune Inc.
Georgiamune is reprogramming immune signaling pathways to redirect the immune system to fi...
Gaithersburg, United Stat...
Inflammx Therapeutics, Inc.
Modulation of Inflammasome mediated Autoinflammation - in Ophthalmology, Nephropathy and...
Tampa, United States
KeifeRx
KeifeRx is a biopharmaceutical company finding disease-modifying treatments for neurodegen...
Mclean, United States
Sitryx
Harnessing the power of cell metabolism to develop groundbreaking disease-modifying therap...
Oxford, United Kingdom
Arcus Biosciences
Biopharmaceutical company developing differentiated molecules and combination therapies fo...
Hayward, United States
Eikon Therapeutics
Eikon is a late-stage clinical biopharmaceutical company dedicated to inventing and develo...
Millbrae, United States
About Azome Therapeutics
Azome Therapeutics is making strides in the biopharma and biotechnology sectors by pioneering innovative solutions to combat severe inflammatory diseases. Founded in 2023, the company is focused on developing selective NLRP3 inflammasome inhibitors. With the slogan, "Developing selective NLRP3 inflammasome inhibitors f...
Development of selective antagonists for inflammatory diseases, Research and drug development for severe pulmonary diseases, Collaboration with scientific and research institutions
Healthcare providers, Patients with severe inflammatory pulmonary diseases, Medical research institutions
Drug Discovery, NLRP3 Inflammasome, Inflammatory Diseases, Selective Antagonists, Inflammasome Inhibitors, RHAMM-Derived Antagonists, Inflammatory Pathways, Therapeutics Development, Early-Stage Company, Biopharmaceuticals, Upstream Priming Signal, Disease Modulation, Inflammation Control
B2B, B2D
Licensing, Performance Based, Project Based
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Azome Therapeutics: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Azome Therapeutics on 28 Jan 2026. The 12 companies listed here were last checked between 11 Sep 2024 and 22 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
